Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time.
Sleep is essential for our physical and mental well being. However, when novel hypnotic drugs are developed, the focus tends to be on the marginal and statistically significant increase in minutes slept during the night instead of the effects on the quality of wakefulness. Recent research on the mechanisms underlying sleep and the control of the sleep-wake cycle has the potential to aid the development of novel hypnotic drugs; however, this potential has not yet been realized. Here, we review the current understanding of how hypnotic drugs act, and discuss how new, more effective drugs and treatment strategies for insomnia might be achieved by taking into consideration the daytime consequences of disrupted sleep.
Wafford
Keith A
KA
Eli Lilly UK, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.
Ebert
Bjarke
B
D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001931:Brain Mapping; D002986:Clinical Trials as Topic; D015928:Cognitive Behavioral Therapy; D018757:GABA Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D058785:GABA-A Receptor Agonists; D006633:Histamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D012894:Sleep Stages / Q000187:drug effects; D014851:Wakefulness / Q000187:drug effects*
D000928:Antidepressive Agents; D018757:GABA Modulators; D058785:GABA-A Receptor Agonists; D006633:Histamine Antagonists; D006993:Hypnotics and Sedatives